Glaxosmithkline Renews and Expands Global License for Simulations Plus Software
News Apr 21, 2008
Simulations Plus, Inc. has announced that GlaxoSmithKline (GSK) has renewed its global multi-year license for Simulations Plus software and has added a new site at its Parsippany, NJ location.
Ron Creeley, vice president of marketing and sales for Simulations Plus, said: “GSK was one of the first GastroPlus™ customers back in 1998 and probably has the largest number of scientists who have gone through GastroPlus training over the years – somewhere in the hundreds. GSK’s scientists are among the most expert users of GastroPlus in the industry, and they have published scientific papers and posters referencing their use of GastroPlus in their important research.”
Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “We appreciate the continued confidence GSK has shown in Simulations Plus over the years, as well as suggestions for improvement they have provided that are now standard features in our programs. This is a time of growing use of simulation and modeling tools in pharmaceutical research, and GSK has been one of the companies at the forefront. We look forward to continuing the excellent relationships we have with GSK scientists worldwide.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019